25462-98-0

Basic information

• Product Name: 4-Pyridinecarbonitrile, 2-chloro-6-Methyl-
• Synonyms: 4-Pyridinecarbonitrile, 2-chloro-6-Methyl-;2-Chloro-6-Methyl-isonicotinonitrile;2-Chloro-6-methyl-4-pyridinecarbonitrile;2-chloro-6-methylpyridine-4-carbonitrile
• CAS NO: 25462-98-0
• Molecular Formula: C7H5ClN2
• Molecular Weight: 152.581
• EINECS: -0
• Mol File: 25462-98-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 238.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• PKA: -0?+-.0.10(Predicted)
• CAS DataBase Reference: 4-Pyridinecarbonitrile, 2-chloro-6-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinecarbonitrile, 2-chloro-6-Methyl-(25462-98-0)
• EPA Substance Registry System: 4-Pyridinecarbonitrile, 2-chloro-6-Methyl-(25462-98-0)

Safety Data

• Hazardous Substances Data: 25462-98-0(Hazardous Substances Data)

Usage

General Description

4-Pyridinecarbonitrile, 2-chloro-6-Methyl- is a chemical compound with the molecular formula C8H6N2Cl. It is a derivative of pyridine, and its structure contains a cyano group and a chlorine atom attached to the pyridine ring. 4-Pyridinecarbonitrile, 2-chloro-6-Methyl- has various industrial applications, including its use as an intermediate in the production of pharmaceuticals, agrochemicals, and other specialty chemicals. Additionally, it is used in the synthesis of other organic compounds and as a building block in chemical reactions. 4-Pyridinecarbonitrile, 2-chloro-6-Methyl- is known to be a toxic and irritant substance and should be handled with proper care in a controlled laboratory setting.

Upstream product

• 26413-58-1 2-chloro-6-methyl-4-pyridinecarbonyl chloride 
• 25462-85-5 2-chloro-6-methylpyridine-4-carboxylic acid 
• 25462-95-7 2-Chlor-6-methyl-isonicotinsaeureamid 
• 1112181-60-8 N-tert-butyl-2-chloro-6-methyl-pyridine-4-carboxamide 

Downstream Products

• 945463-94-5 2-ethyl-6-methylpyridine-4-carbonitrile 
• 1112174-77-2 N-(4-fluoro-3-methoxybenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-59-0 N-(4-fluoro-3-(trifluoromethyl)benzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-56-7 N-(4-fluoro-3-methylbenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-53-4 N-(3,4-difluorobenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-31-8 N-(3-(trifluoromethyl)benzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-40-9 N-(3-methylbenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-37-4 N-(3-chlorobenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112174-95-4 N-(4-fluorobenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)-methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112182-62-3 4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinic acid 
• 1112173-02-0 trans-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methyl-pyridin-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylic acid 
• 1112171-88-6 N-(3-methoxybenzyl)-4-(2-(((cis)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 
• 1112182-36-1 tert-butyl (cis)-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylcarbamate 
• 1112171-08-0 N-(3-methoxybenzyl)-4-(2-(((trans)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide 

Relevant articles and documents

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis

Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.

HETEROARYLS AND THEIR USE AS PI3K INHIBITORS

This invention provides compounds of formula (IA) or (IB): wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis

Potent, highly selective and orally-bioavailable MMP-13 inhibitors have been identified based upon a (pyridin-4-yl)-2H-tetrazole scaffold. Co-crystal structure analysis revealed that the inhibitors bind at the S1′ active site pocket